ScandiBio Featured on Life Science Sweden’s 2026 Phase III Watchlist
Sweden’s life science sector is entering a decisive phase. A recent overview from Life Science Sweden highlights that a growing number of Swedish life science companies now have drug candidates in Phase III clinical development, including SOBI, AstraZeneca, Affibody and others.
At the same time, Phase III remains rare in Sweden. According to SwedenBIO’s annual report The Swedish Drug Discovery and Development Pipeline 2026, of the 518 drug development projects currently active in Sweden, only around three percent are in Phase III. Historically, many Swedish companies have chosen to exit or partner before reaching this stage, making each late-stage program particularly noteworthy.
Within these late-stage efforts, Alzheimer’s disease stands out as one of the most significant therapeutic areas undergoing rapid market expansion. Sweden has played a disproportionate important role in Alzheimer’s research for decades, spanning foundational genetics (discovery of the Swedish and Arctic mutations), the FDA-approved therapy lecanemab from BioArctic, in addition to biomarker discovery which has proved foundational to advances such as the recently FDA-cleared blood test from Roche.
Yet only two Swedish companies currently have Alzheimer’s drug candidates in Phase III. BioArctic is conducting a Phase III trial of lecanemab for presymptomatic treatment, and ScandiBio is running a Phase III trial of the novel compound CMA for Alzheimer’s disease.
What differentiates ScandiBio is its scientific origin and mechanism. While much of the Alzheimer’s field has historically focused on amyloid and tau, ScandiBio’s program builds on metabolic and systems-level biology, supported by large-scale protein mapping and computational modeling based on the Human Protein Atlas.
ScandiBio’s approach reflects a broader shift in Alzheimer’s R&D toward complementary, multimodal approaches. It also mirrors a wider trend noted in the SwedenBIO pipeline report: life science innovation increasingly combines deep biology, advanced analytics, and translational clinical thinking, rather than relying on single-target approaches alone.
Read more
Svenska läkemedel i fas III – här är studierna att hålla ögonen på (web article in Swedish)
Svenska läkemedel i fas III – här är studierna att hålla ögonen på (PDF in Swedish)
Swedish drugs in phase III – here are the studies to keep an eye on (PDF in English)
